<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02417844</url>
  </required_header>
  <id_info>
    <org_study_id>527.89</org_study_id>
    <nct_id>NCT02417844</nct_id>
  </id_info>
  <brief_title>Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fed Male.</brief_title>
  <official_title>Single Center, Single Dose, Open-label, Randomized, Two-way Crossover Study to Determine Bioequivalence of Two Formulations Containing Tamsulosin HCl 04.mg MR Capsules in at Least 30 Healthy Male Subjects Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Two tamsulosin HClformulations will be tested in fed state
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Measured Concentration (Cmax)</measure>
    <time_frame>Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration</time_frame>
    <description>Maximum measured concentration of analyte in plasma (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve From 0 to the Time of the Last Quantifiable Concentration (AUC0-tz)</measure>
    <time_frame>Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration</time_frame>
    <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable concentration (AUC0-tz)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve From 0 Extrapolated to Infinity (AUC0-inf)</measure>
    <time_frame>Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration</time_frame>
    <description>Area under the concentration-time curve of analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax)</measure>
    <time_frame>Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration</time_frame>
    <description>Time from last dosing to the maximum plasma concentration (tmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Rate Constant (λz)</measure>
    <time_frame>Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration</time_frame>
    <description>Terminal elimination rate constant in plasma (λz)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Elimination Half-life (t1/2)</measure>
    <time_frame>Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration</time_frame>
    <description>Apparent terminal elimination half-life of the analyte in plasma (t1/2)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Tamsulosin HCl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tamsulosin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamsulosin (Astellas)</intervention_name>
    <arm_group_label>Tamsulosin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin HCL</intervention_name>
    <arm_group_label>Tamsulosin HCl</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Health male volunteers 18 years and older

        Exclusion criteria:

        History of hypersensitivity or allergy to IMP or its excipients or any related medication
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <removed_countries>
    <country>South Africa</country>
  </removed_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 13, 2015</study_first_submitted>
  <study_first_submitted_qc>April 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2015</study_first_posted>
  <results_first_submitted>March 12, 2020</results_first_submitted>
  <results_first_submitted_qc>April 15, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 17, 2020</results_first_posted>
  <last_update_submitted>April 15, 2020</last_update_submitted>
  <last_update_submitted_qc>April 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Each treatment was administered after consumption of a high-fat, high-calorie breakfast.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tamsulosin HCl (Test) / Flomax Relief (Reference)</title>
          <description>Oral administration of Tamsulosin hydrochloride (HCl) 0.4mg modified release (MR) capsule followed by oral administration of Flomax Relief modified release (MR) 0.4mg capsule (tamsulosin MR capsules).</description>
        </group>
        <group group_id="P2">
          <title>Flomax Relief (Reference) / Tamsulosin HCl (Test)</title>
          <description>Oral administration of Flomax Relief modified release (MR) 0.4mg capsule (tamsulosin MR capsules) followed by oral administration of Tamsulosin hydrochloride (HCl) 0.4mg modified release (MR) capsule.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set which included all subjects who received at least one dose of investigational medicinal product.</population>
      <group_list>
        <group group_id="B1">
          <title>All Subjects</title>
          <description>Subjects each received two treatments which were each administered orally and separated by a washout period of 7 days. The treatments were:
Flomax Relief (Reference): Flomax Relief modified release (MR) 0.4mg capsule (tamsulosin MR capsules).
Tamsulosin hydrochloride (HCl) (Test): Tamsulosin HCl 0.4mg modified release (MR) capsule.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.6" spread="5.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Measured Concentration (Cmax)</title>
        <description>Maximum measured concentration of analyte in plasma (Cmax)</description>
        <time_frame>Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set which included all subjects who had evaluable PK data for both treatment periods.</population>
        <group_list>
          <group group_id="O1">
            <title>Tamsulosin HCl (Test)</title>
            <description>Oral administration of Tamsulosin hydrochloride (HCl) 0.4mg modified release (MR) capsule.</description>
          </group>
          <group group_id="O2">
            <title>Flomax Relief (Reference)</title>
            <description>Oral administration of Flomax Relief modified release (MR) 0.4mg capsule (tamsulosin MR capsule).</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Measured Concentration (Cmax)</title>
          <description>Maximum measured concentration of analyte in plasma (Cmax)</description>
          <population>Pharmacokinetic (PK) set which included all subjects who had evaluable PK data for both treatment periods.</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8826" spread="31.8"/>
                    <measurement group_id="O2" value="8856" spread="34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence (legacy)</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence range of 80% to 125%.</non_inferiority_desc>
            <param_type>Geometric mean ratio (%)</param_type>
            <param_value>99.66</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>19.15</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.19</ci_lower_limit>
            <ci_upper_limit>107.74</ci_upper_limit>
            <estimate_desc>The standard deviation in the statistical analysis is actually the intra-individual coefficient of variation.
Ratio calculated as test divided by reference.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve From 0 to the Time of the Last Quantifiable Concentration (AUC0-tz)</title>
        <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable concentration (AUC0-tz)</description>
        <time_frame>Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration</time_frame>
        <population>PK set</population>
        <group_list>
          <group group_id="O1">
            <title>Tamsulosin HCl (Test)</title>
            <description>Oral administration of Tamsulosin hydrochloride (HCl) 0.4mg modified release (MR) capsule.</description>
          </group>
          <group group_id="O2">
            <title>Flomax Relief (Reference)</title>
            <description>Oral administration of Flomax Relief modified release (MR) 0.4mg capsule (tamsulosin MR capsule).</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From 0 to the Time of the Last Quantifiable Concentration (AUC0-tz)</title>
          <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable concentration (AUC0-tz)</description>
          <population>PK set</population>
          <units>h*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164700" spread="42.4"/>
                    <measurement group_id="O2" value="165400" spread="43.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence (legacy)</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence range of 80% to 125%.</non_inferiority_desc>
            <param_type>Geometric mean ratio (%)</param_type>
            <param_value>99.58</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>13.51</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.23</ci_lower_limit>
            <ci_upper_limit>105.24</ci_upper_limit>
            <estimate_desc>The standard deviation in the statistical analysis is actually the intra-individual coefficient of variation.
Ratio calculated as test divided by reference.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve From 0 Extrapolated to Infinity (AUC0-inf)</title>
        <description>Area under the concentration-time curve of analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf).</description>
        <time_frame>Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration</time_frame>
        <population>PK set</population>
        <group_list>
          <group group_id="O1">
            <title>Tamsulosin HCl (Test)</title>
            <description>Oral administration of Tamsulosin hydrochloride (HCl) 0.4mg modified release (MR) capsule.</description>
          </group>
          <group group_id="O2">
            <title>Flomax Relief (Reference)</title>
            <description>Oral administration of Flomax Relief modified release (MR) 0.4mg capsule (tamsulosin MR capsule).</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From 0 Extrapolated to Infinity (AUC0-inf)</title>
          <description>Area under the concentration-time curve of analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf).</description>
          <population>PK set</population>
          <units>h*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170100" spread="44.1"/>
                    <measurement group_id="O2" value="171000" spread="45.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence (legacy)</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence range of 80% to 125%.</non_inferiority_desc>
            <param_type>Geometric mean ratio (%)</param_type>
            <param_value>99.48</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>14.12</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.90</ci_lower_limit>
            <ci_upper_limit>105.39</ci_upper_limit>
            <estimate_desc>The standard deviation in the statistical analysis is actually the intra-individual coefficient of variation.
Ratio calculated as test divided by reference.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Plasma Concentration (Tmax)</title>
        <description>Time from last dosing to the maximum plasma concentration (tmax).</description>
        <time_frame>Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration</time_frame>
        <population>PK set</population>
        <group_list>
          <group group_id="O1">
            <title>Tamsulosin HCl (Test)</title>
            <description>Oral administration of Tamsulosin hydrochloride (HCl) 0.4mg modified release (MR) capsule.</description>
          </group>
          <group group_id="O2">
            <title>Flomax Relief (Reference)</title>
            <description>Oral administration of Flomax Relief modified release (MR) 0.4mg capsule (tamsulosin MR capsule).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentration (Tmax)</title>
          <description>Time from last dosing to the maximum plasma concentration (tmax).</description>
          <population>PK set</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.51" lower_limit="4.00" upper_limit="12.01"/>
                    <measurement group_id="O2" value="8.00" lower_limit="4.00" upper_limit="24.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Rate Constant (λz)</title>
        <description>Terminal elimination rate constant in plasma (λz)</description>
        <time_frame>Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration</time_frame>
        <population>PK set</population>
        <group_list>
          <group group_id="O1">
            <title>Tamsulosin HCl (Test)</title>
            <description>Oral administration of Tamsulosin hydrochloride (HCl) 0.4mg modified release (MR) capsule.</description>
          </group>
          <group group_id="O2">
            <title>Flomax Relief (Reference)</title>
            <description>Oral administration of Flomax Relief modified release (MR) 0.4mg capsule (tamsulosin MR capsule).</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Rate Constant (λz)</title>
          <description>Terminal elimination rate constant in plasma (λz)</description>
          <population>PK set</population>
          <units>1/hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="21.6" lower_limit="0.03" upper_limit="0.08"/>
                    <measurement group_id="O2" value="0.05" spread="21.9" lower_limit="0.04" upper_limit="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Elimination Half-life (t1/2)</title>
        <description>Apparent terminal elimination half-life of the analyte in plasma (t1/2)</description>
        <time_frame>Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration</time_frame>
        <population>PK set</population>
        <group_list>
          <group group_id="O1">
            <title>Tamsulosin HCl (Test)</title>
            <description>Oral administration of Tamsulosin hydrochloride (HCl) 0.4mg modified release (MR) capsule.</description>
          </group>
          <group group_id="O2">
            <title>Flomax Relief (Reference)</title>
            <description>Oral administration of Flomax Relief modified release (MR) 0.4mg capsule (tamsulosin MR capsule).</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Elimination Half-life (t1/2)</title>
          <description>Apparent terminal elimination half-life of the analyte in plasma (t1/2)</description>
          <population>PK set</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.16" spread="21.6" lower_limit="9.12" upper_limit="20.10"/>
                    <measurement group_id="O2" value="13.21" spread="21.9" lower_limit="6.93" upper_limit="18.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 72 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tamsulosin HCl (Test)</title>
          <description>Oral administration of Tamsulosin hydrochloride (HCl) 0.4mg modified release (MR) capsule.</description>
        </group>
        <group group_id="E2">
          <title>Flomax Relief (Reference)</title>
          <description>Oral administration of Flomax Relief modified release (MR) 0.4mg capsule (tamsulosin MR capsules).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

